Cullinan Therapeutics (CGEM) stock: insider trades, news & valuation
Net buyingShare price and insider trades
Cullinan Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $13.3M and 5 sold $2.5M of CGEM stock on the open market.
Get emailed when insiders cluster-buy stocks like CGEM
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CGEM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $923K | 3 |
| Q2 2026 | — | 0 | $117K | 2 |
| Q1 2026 | — | 0 | $1.2M | 15 |
| Q4 2025 | $13.3M | 8 | $307K | 8 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 Cullinan Therapeutics, Inc. insiders reported open-market purchases totaling $13.3M, while 5 insiders reported sales totaling $2.5M. Among insiders with enough purchase history to measure, Lynx1 Capital Management Lp (10% Owner) has the highest Insider Score at 89. 16 of 28 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 10SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 8,000158,844 held (−5%) | $21.57 | $173K | -28.0% | — |
| Aug 14SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 30,000162,844 held (−16%) | $20.26 | $608K | -23.3% | — |
| Jul 7SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 8,000162,844 held (−5%) | $17.82 | $143K | -12.9% | — |
| May 6SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 7,800167,044 held (−4%) | $14.60 | $114K | +6.4% | — |
| May 6SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 200166,844 held (−0%) | $15.58 | $3K | -0.3% | — |
| Mar 9SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 8,000170,844 held (−4%) | $15.68 | $125K | -1.0% | — |
| Feb 26SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 1,780174,844 held (−1%) | $14.14 | $25K | +9.8% | — |
| Feb 25SEC | Nadim AhmedCEO, President | Sell | 13,515390,803 held (−3%) | $14.47 | $196K | +7.3% | — |
| Feb 25SEC | Jeffrey Alan JonesChief Medical Officer | Sell | 4,582159,968 held (−3%) | $14.47 | $66K | +7.3% | — |
| Feb 25SEC | Jacquelyn L SumerGeneral Counsel | Sell | 3,601128,089 held (−3%) | $14.47 | $52K | +7.3% | — |
| Feb 25SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 3,601176,624 held (−2%) | $14.47 | $52K | +7.3% | — |
| Feb 25SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 1,752180,225 held (−1%) | $13.99 | $25K | +11.0% | — |
| Feb 23SEC | Nadim AhmedCEO, President | Sell | 16,381404,318 held (−4%) | $13.62 | $223K | +14.0% | — |
| Feb 23SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 8,000181,977 held (−4%) | $14.30 | $114K | +8.6% | — |
| Feb 23SEC | Jeffrey Alan JonesChief Medical Officer | Sell | 4,982164,550 held (−3%) | $13.62 | $68K | +14.0% | — |
| Feb 23SEC | Mary Kay FentonCFO | Sell | 4,398126,380 held (−3%) | $13.62 | $60K | +14.0% | — |
| Feb 23SEC | Jacquelyn L SumerGeneral Counsel | Sell | 3,742131,690 held (−3%) | $13.62 | $51K | +14.0% | — |
| Feb 23SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 3,742181,977 held (−2%) | $13.62 | $51K | +14.0% | — |
| Feb 13SEC | Jennifer MichaelsonChief Scientific Officer | Sell | 416128,219 held (−0%) | $12.03 | $5K | +29.1% | — |
| Jan 23SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 4,000128,635 held (−3%) | $12.30 | $49K | +26.3% | — |
| Dec 29SEC | Nadim AhmedCEO, President | Sell | 9,922420,699 held (−2%) | $10.01 | $99K | +55.1% | — |
| Dec 22SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 1,345132,635 held (−1%) | $10.01 | $13K | +55.1% | — |
| Dec 19SEC | Jeffrey Alan JonesChief Medical Officer | Sell | 4,632169,532 held (−3%) | $9.67 | $45K | +60.6% | — |
| Dec 19SEC | Jacquelyn L SumerGeneral Counsel | Sell | 3,480135,432 held (−3%) | $9.67 | $34K | +60.6% | — |
| Dec 19SEC | Jennifer MichaelsonChief Scientific Officer | Sell | 2,898133,980 held (−2%) | $9.67 | $28K | +60.6% | — |
| Dec 16SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 2,148137,873 held (−2%) | $12.38 | $27K | +25.4% | — |
| Dec 16SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 995136,878 held (−1%) | $11.90 | $12K | +30.5% | — |
| Nov 25SEC | Jennifer MichaelsonChief Scientific Officer | Sell Plan | 4,000138,004 held (−3%) | $12.30 | $49K | +26.3% | — |
| Oct 30SEC | Weston Nichols10% Owner | Buy | 165,6678,963,500 held (+2%) | $8.40 | $1.4M | +84.9% | 83 |
| Oct 21SEC | Lynx1 Capital Management Lp10% Owner | Buy | 150,0008,765,616 held (+2%) | $8.86 | $1.3M | +75.3% | 89 |
| Oct 21SEC | Lynx1 Capital Management Lp10% Owner | Buy | 51,5008,615,616 held (+1%) | $7.94 | $409K | +95.6% | 89 |
| Oct 21SEC | Lynx1 Capital Management Lp10% Owner | Buy | 32,2178,797,833 held (+0%) | $7.84 | $253K | +98.1% | 89 |
| Oct 21SEC | Lynx1 Capital Management Lp10% Owner | Buy | 15,0328,564,116 held (+0%) | $7.59 | $114K | +104.6% | 89 |
| Oct 10SEC | Lynx1 Capital Management Lp10% Owner | Buy | 626,0438,271,786 held (+8%) | $6.70 | $4.2M | +131.8% | 89 |
| Oct 10SEC | Lynx1 Capital Management Lp10% Owner | Buy | 556,3007,645,743 held (+8%) | $6.46 | $3.6M | +140.4% | 89 |
| Oct 10SEC | Lynx1 Capital Management Lp10% Owner | Buy | 277,2988,549,084 held (+3%) | $7.36 | $2.0M | +111.0% | 89 |
Insiders at Cullinan Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Lynx1 Capital Management Lp10% Owner | $11.9M | — | Oct 21, 2025 | 89 |
| Weston Nichols10% Owner | $1.4M | — | Oct 30, 2025 | 83 |
| Jennifer MichaelsonChief Scientific Officer | — | $1.6M | Sep 10, 2026 | — |
| Nadim AhmedCEO, President | — | $518K | Feb 25, 2026 | — |
| Jeffrey Alan JonesChief Medical Officer | — | $179K | Feb 25, 2026 | — |
| Jacquelyn L SumerGeneral Counsel | — | $137K | Feb 25, 2026 | — |
| Mary Kay FentonCFO | — | $60K | Feb 23, 2026 | — |
CGEM stock: common questions
Are Cullinan Therapeutics, Inc. insiders buying CGEM stock?
In the past 12 months, 2 insiders reported open-market purchases of CGEM worth $13.3M. The latest was 10% Owner Weston Nichols bought $1.4M of CGEM at $8.40 — first open-market purchase in our records.
Are Cullinan Therapeutics, Inc. insiders selling CGEM stock?
5 insiders reported sales worth $2.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CGEM's 52-week range?
Over the past year CGEM has traded between $7.05 and $22.95. It last closed at $15.53 on Oct 9, 2026.